In combination w/ other chemotherapeutics in patients w/ metastatic testicular & ovarian tumors who have already received appropriate surgical &/or radio therapeutic procedures. Monotherapy for secondary therapy in patients w/ metastatic ovarian tumors refractory to standard chemotherapy w/o previous cisplatin therapy. Monotherapy for transitional cell bladder cancer, no longer amenable to local treatments eg, surgery &/or RT.
IV Metastatic testicular cancer In combination w/ other chemotherapeutics: 20 mg/m2 daily for 5 days/cycle. Metastatic ovarian cancer Monotherapy: 100 mg/m2/cycle every 4 wk. Combination w/ cyclophosphamide: 75-100 mg/m2/cycle every 4 wk. Advanced bladder cancer Monotherapy: 50-70 mg/m2/cycle every 3-4 wk. Heavily pretreated patients Initially 50 mg/m2/cycle every 4 wk.
View Kemoplat overdosage for action to be taken in the event of an overdose.
Contraindications
History of hypersensitivity to cisplatin or other platinum-containing compd. Patients w/ myelosuppression; hearing impairment. Preexisting renal impairment.
Anaphylactic-like reactions w/in min of administration. Not to be administered more frequently than once every 3-4 wk. Nephrotoxicity; severe neuropathies in patients using higher doses or greater dose frequencies than recommended dose; ototoxicity; myelosuppression, nausea & vomiting. Adequately hydrate patients before & for 24 hr after administration. Measure serum creatinine, BUN, CrCl & Mg, Na, K & Ca levels prior to initiating therapy & to each subsequent course. Perform audiometric testing prior to initiating therapy & to each subsequent dose. Concomitant use w/ aminoglycosides. Renal insufficiency. Pregnancy. Not to be initiated in lactation. Childn (ototoxicity).
Sign Out
